Bionxt talks up global patent coverage for ODF

Executive Summary

• Bionxt Solutions Inc. announces a strategic transition into the commercialization phase, supported by a broadened global patent portfolio for its proprietary sublingual drug delivery platform.
• The company has secured significant patent protections in key jurisdictions, including a European patent covering up to 39 EPC member states and a Eurasian patent covering eight member states, creating an addressable market of nearly one billion people.
• Bionxt has filed for "Track One" fast-track examination with the USPTO, aiming for a final disposition within 9-12 months, while parallel applications are progressing in Canada, Japan, Australia, and New Zealand.

Key Details

• Lead Product: BNT23001, a sublingual cladribine ODF (orally disintegrating film), targeting multiple sclerosis (MS) and myasthenia gravis (MG).
• European Patent: European Patent No. 4539857 granted on March 11, 2026, covering ODF technology across up to 39 EPC member states.
• Eurasian Patent: Patent No. 051510 granted on November 14, 2025, providing protection across eight member states, including Russia and Kazakhstan.
• US Patent Strategy: Completed a "Track One" priority filing with the USPTO for accelerated examination, with an expected timeline of 9-12 months to final disposition.
• International Applications: National phase applications under the Patent Cooperation Treaty are progressing in Canada, Japan, Australia, and New Zealand.
• Platform Technology: Proprietary sublingual thin-film technology designed to improve bioavailability, reduce variability, and enhance patient compliance compared to conventional oral tablets or injectables.
• Expanded Indications: The US filing extends coverage beyond MS to include myasthenia gravis and lupus nephritis.
• Commercial Strategy: Pursuing a partnership-driven approach including licensing agreements, co-development collaborations, and royalty-based supply arrangements with pharmaceutical partners.
• Company Focus: Bioscience innovator focused on next-generation drug delivery platforms, including sublingual thin films, transdermal patches, oral tablets, and a targeted chemotherapy platform.

Notable Quotes

• "We have reached a defining moment for Bionxt," said Hugh Rogers, chief executive officer of Bionxt Solutions. "Our global patent estate, combined with the accelerated U.S. pathway, provides the foundation to move decisively into commercialization. We are now focused on translating our IP strength into strategic partnerships and long-term revenue opportunities."